Among the companies with shares expected to actively trade in Wednesday’s session are Navistar International Corp.(NAV), Smith & Wesson Holding Corp.(SWHC) and USEC Inc.(USU)
Navistar said its fiscal first-quarter loss widened as its North America truck segment was hurt by reduced volume partly linked to the company’s lower-emission transition and weaker demand for military products. Results missed expectations, pushing shares down 4.7% to $36 premarket.
Smith & Wesson said its fiscal third-quarter earnings rose 43% as handgun sales continued to grow and margins strengthened. The results beat expectations, pushing shares up 9.8% to $12.95 premarket.
USEC filed for Chapter 11 under the U.S. bankruptcy code as the uranium supplier moves forward with a prepackaged restructuring agreement reached with some creditors last year. Shares plunged 32% to $3.80 premarket.
AeroVironment Inc.'s(AVAV) fiscal third-quarter profit nearly tripled as the pilotless-drones maker reported a sharp jump in revenue and booked a gain on an investment. Adjusted profit and revenue results for the latest quarter easily exceeded Wall Street’s expectations. Shares climbed 10% to $34.90 in light premarket trading.
Bob Evans Farms Inc.(BOBE) posted a sharp decline in sales in its fiscal third quarter, hurt by severe winter weather, and outlined plans to cut jobs and reduce additional costs. Shares dropped 6.3% to $48.50 premarket.
Canadian Solar Inc.(CSIQ) swung to a profit in the fourth quarter, but warned of weather-related impacts on its top line in the current period. Shares of the company fell 8.4% to $40 in recent premarket trading.
Dara Biosciences Inc.(DARA) signed a Medicare Part D prescription drug reimbursement agreement with Wellcare Health Plans Inc.(WCG), providing its Soltamox breast-cancer drug with access to the managed-care company’s extensive network. The pharmaceutical company’s shares rose 19% to $3.45 premarket.
XOMA Corp.(XOMA) said it swung to a loss in the fourth quarter, as an increase in operating expenses offset revenue gains. The drug developer’s losses were wider than expected by the market, sending shares down 20% to $7.54 premarket.
Yongye International Inc.(YONG) said its shareholders rejected a go-private deal with Full Alliance International Ltd. that values the Chinese fertilizer company at $339 million. Shares declined 13% to $5.68 premarket.